ArticleCNS neuroscience & therapeutics2026
GALNT3 Inhibits the Progression of Cerebral Ischemia-Reperfusion Injury by Stabilizing TREM2 via O-GalNAc Glycosylation.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveCerebral ischemia-reperfusion injury (CIRI) is a major cause of poor outcome after ischemic stroke, and effective therapeutic targets are lacking. This study aimed to investigate the role of polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) in CIRI.
methodsThe mouse transient middle cerebral artery occlusion/reperfusion (tMCAO/R) model was established, and transcriptomic analysis of the peri-infarct cortex was performed to screen target genes. In vivo experiments, neurological scoring and TTC staining were used to assess the effects of GALNT3 on brain injury. In vitro, microglial HMC3 cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) were used to model CIRI and further analyze the effects of GALNT3 on macrophage polarization and inflammatory factor expression.
resultsTranscriptomic analysis of the peri-infarct cortex in the tMCAO/R model identified GALNT3 as a significantly down-regulated gene. GALNT3 overexpression reduced infarct volume, improved neurological function, and suppressed neuronal apoptosis, oxidative stress, and neuroinflammation in tMCAO/R mice. Subsequently, GALNT3 was further demonstrated to inhibit microglial M1 polarization and down-regulate inflammatory factors in the OGD/R model. Further mechanism investigation revealed that GALNT3, acting as a mucin type O glycosylation initiating enzyme, directly interacted with triggering receptor expressed on myeloid cells 2 (TREM2) and promoted its O GalNAc glycosylation, predominantly at serine 147, thereby enhancing TREM2 protein stability. TREM2 knockdown stimulated inflammatory responses that were inhibited by GALNT3 overexpression in OGD/R-treated microglia.
conclusionThis study revealed a novel GALNT3/TREM2 regulatory axis that restricts neuroinflammation and injury after CIRI, highlighting GALNT3-mediated O-glycosylation as a potential therapeutic strategy for CIRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.